Apollo Life Science's Human Proteins Lead To Improved Cancer Treatment by Boosting Stem Cell Growth

21-Nov-2006

Apollo Life Sciences Ltd announced that initial studies showed two of its human proteins outperform competitor proteins in stimulating faster growth in numbers of blood-producing stem cells, which are mainly used to generate white blood cells for chemotherapy patients.

"This means that Apollo's proteins potentially offer cancer patients the chance to increase their rate of chemotherapy, leading to improved and even lifesaving outcomes," Dr Greg Russell-Jones, Apollo's Science Director, said.

A new study undertaken by Apollo showed that two of its human proteins (hcx(TM)) are up to 53% more effective than similar proteins which competitors produce from non-human cells (p-value less than 0.00021). In the series of in vitro experiments, CD34- positive haematopoietic stem cells enriched from umbilical cord blood were cultured with a medium containing Apollo's fully G-CSF and SCF (granulocyte-colony stimulating factor and stem cell factor) with the same proteins produced from bacteria by competitors. Viable cells were counted at the end of seven days.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances